Journal article icon

Journal article

Subclassification of epithelioid sarcoma with potential therapeutic impact

Abstract:
Epithelioid sarcoma is a rare and aggressive mesenchymal tumour, the genetic hallmark of which is the loss of expression of SMARCB1, a key member of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodelling complex. Hampered by its rarity, epithelioid sarcoma has received little research attention and therapeutic options for this disease remain limited. SMARCB1-deficient tumours also include malignant rhabdoid tumour, atypical teratoid and rhabdoid tumour, epithelioid malignant peripheral nerve sheath tumour, and poorly differentiated chordoma. Histologically, it can be challenging to distinguish epithelioid sarcoma from malignant rhabdoid tumour and other SMARCB1-deficient tumours, whereas methylation profiling shows that they represent distinct entities and facilitates their classification. Methylation studies on SMARCB1-deficient tumours, although not including epithelioid sarcomas, reported methylation subgroups which resulted in new clinical stratification and therapeutic approaches. In addition, emerging evidence indicates that immunotherapy, including immune checkpoint inhibitors, represents a promising therapeutic strategy for SMARCB1-deficient tumours. Here, we show that some epithelioid sarcomas share methylation patterns of malignant rhabdoid tumours indicating that this could help to distinguish these entities and guide treatment. Using gene expression data, we also showed that the immune environment of epithelioid sarcoma is characterised by a predominance of CD8+ lymphocytes and M2 macrophages. These findings have potential implications for the management of patients with epithelioid sarcoma. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1002/path.6135

Authors

More by this author
Role:
Author
ORCID:
0000-0002-4227-6051
More by this author
Role:
Author
ORCID:
0000-0002-1671-9488
More by this author
Role:
Author
ORCID:
0000-0002-4942-9540
More by this author
Role:
Author
ORCID:
0000-0003-0495-9457
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-8926-6256


Publisher:
Wiley
Journal:
The Journal of Pathology More from this journal
Volume:
260
Issue:
4
Pages:
368-375
Publication date:
2023-06-14
DOI:
EISSN:
1096-9896
ISSN:
0022-3417


Language:
English
Keywords:
Pubs id:
2374029
Local pid:
pubs:2374029
Source identifiers:
W4380730773
Deposit date:
2026-02-15
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP